• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Glycosylation signature of plasma IgA of critically ill COVID-19 patients

tetano

Editor, Senior Moderator
Front Immunol


. 2024 Oct 24:15:1439248.
doi: 10.3389/fimmu.2024.1439248. eCollection 2024. Glycosylation signature of plasma IgA of critically ill COVID-19 patients

Daniel P Potaczek[SUP] 1 2 3 [/SUP], Bianca D M van Tol[SUP] 4 [/SUP], David Falck[SUP] 4 [/SUP], Christina Krolczik[SUP] 1 [/SUP], Kristina Zlatina[SUP] 5 [/SUP], Wilhelm Bertrams[SUP] 6 [/SUP], Jochen Wilhelm[SUP] 7 [/SUP], Bernd Schmeck[SUP] 6 [/SUP], Benjamin Seeliger[SUP] 8 9 [/SUP], Sascha David[SUP] 10 [/SUP], Chrysanthi Skevaki[SUP] 11 [/SUP], Elisabeth Mack[SUP] 12 [/SUP], Werner Seeger[SUP] 7 13 [/SUP], Liliana Schaefer[SUP] 14 [/SUP], Sebastian P Galuska[SUP] 5 [/SUP], Manfred Wuhrer[SUP] 4 [/SUP], Małgorzata Wygrecka[SUP] 1 7 13 [/SUP]



Affiliations
Abstract

Thromboembolic complications are common in severe COVID-19 and are thought to result from excessive neutrophil-extracellular-trap (NET)-driven immunothrombosis. Glycosylation plays a vital role in the efficiency of immunoglobulin A (IgA) effector functions, with significant implications for NET formation in infectious diseases. This study represents the first comprehensive analysis of plasma IgA glycosylation during severe SARS-CoV-2 or Influenza A infection, revealing lower sialylation and higher galactosylation of IgA1 O-glycans in acute respiratory distress syndrome (ARDS), regardless of the underlying cause of the disease. Importantly, N-glycans displayed an infection-specific pattern, with N47 of IgA2 showing diminished sialylation and bisection, and N340/N327 of IgA1/2 demonstrating lower fucosylation and antennarity along with higher non-complex glycans in COVID-19 compared to Influenza. Notably, COVID-19 IgA possessed strong ability to induce NET formation and its glycosylation patterns correlated with extracellular DNA levels in plasma of critically ill COVID-19 patients. Our data underscores the necessity of further research on the role of IgA glycosylation in the modulation of pathogen-specific immune responses in COVID-19 and other infectious diseases.

Keywords: ARDS; COVID-19; NETosis; glycosylation; immunoglobulin A.

 
Back
Top Bottom